文献速递肿瘤 PET/CT

成纤维细胞活化蛋白靶向[18F]FAP-2286 PET/CT用于肺癌评估:与[18F]FDG PET/CT的对比研究

Fibroblast activation Protein-Targeted PET/CT using [18 F]FAP-2286 for the evaluation of lung cancer: A comparative study with [18 F]FDG PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-08-07

本研究纳入30例疑似肺癌患者,比较[18F]FAP-2286与[18F]FDG PET/CT的诊断效能。结果显示[18F]FAP-2286在原发灶靶本比更高,转移性淋巴结检出率较低但真阳性率更高,骨和脑转移检出率更高,结论认为其可能作为肺癌综合评估的有价值替代方法。

要点

  • [18F]FAP-2286在原发灶的靶本比(11.60±6.02)显著高于[18F]FDG(5.80±3.08),P<0.001。
  • [18F]FAP-2286对转移性淋巴结检出率67.46%(85/126)低于[18F]FDG的86.51%(109/126),P<0.001;真阳性率95.29%高于68.81%,P<0.001。
  • [18F]FAP-2286对骨转移(98.80% vs. 72.46%)和脑转移(100% vs. 72.73%)检出率高于[18F]FDG。

核心结论

  • 与[18F]FDG相比,[18F]FAP-2286 PET/CT在检测骨转移方面表现更优,并提供更准确的N和M分期。
  • 这些发现提示[18F]FAP-2286 PET/CT可能作为肺癌患者综合评估的有价值替代方法。

研究设计与样本

  • 本研究为对比研究,纳入30例疑似肺癌患者(18男12女,中位年龄64岁,IQR 35-81),均接受[18F]FAP-2286和[18F]FDG PET/CT,其中初始分期27例、复发检测3例。
  • 以组织病理学和临床随访为参考标准评估诊断效能,定量分析包括最大标准化摄取值(SUVmax)和靶本比(TBR)。

主要发现

  • [18F]FAP-2286的原发灶TBR为11.60±6.02,[18F]FDG为5.80±3.08,P<0.001;SUVmax分别为15.20±8.25和13.81±7.73,P=0.524。
  • [18F]FAP-2286对转移性淋巴结的检出率为67.46%(85/126),[18F]FDG为86.51%(109/126),P<0.001;真阳性率分别为95.29%和68.81%,P<0.001。
  • [18F]FAP-2286对骨转移检出率为98.80%,[18F]FDG为72.46%;对脑转移检出率分别为100%和72.73%。

临床怎么用

  • 作者认为[18F]FAP-2286 PET/CT可能作为肺癌患者综合评估的有价值替代方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: FAP-2286, which is a novel cyclic peptide that targets fibroblast activation protein (FAP), demonstrates enhanced plasma stability and improved receptor selectivity compared with small-molecule FAP inhibitors (FAPIs). Although [18 F]FAP-2286 exhibits benefits due to the favorable characteristics of fluorine-18-labeled tracers, its diagnostic performance in lung cancer remains to be fully elucidated. This study aimed to compare the diagnostic efficacy of [18 F]FAP-2286 PET/CT with that of [18 F]FDG PET/CT in lung cancer patients. METHODS: Thirty patients with suspected lung cancer (18 men and 12 women; median age: 64 years [IQR: 35-81]) underwent both [18 F]FAP-2286 and [18 F]FDG PET/CT for initial staging (n = 27) or the detection of recurrence (n = 3). Diagnostic performance was assessed using histopathology and clinical follow-up as reference standards. The quantitative analysis included the maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR). RESULTS: Compared with [18 F]FDG, [18 F]FAP-2286 PET/CT significantly increased the TBR in primary tumors (11.60 ± 6.02 vs. 5.80 ± 3.08; P < 0.001), whereas the SUVmax was not significantly different (15.20 ± 8.25 vs. 13.81 ± 7.73; P = 0.524). Although [18 F]FAP-2286 PET/CT demonstrated a lower detection rate for metastatic lymph nodes (67.46% [85/126] vs. 86.51% [109/126]; P < 0.001), it exhibited a higher true positive rate (95.29% vs. 68.81%; P < 0.001). For distant metastases, [18 F]FAP-2286 PET/CT demonstrated superior detection of bone (98.80% vs. 72.46%) and brain lesions (100% vs. 72.73%). CONCLUSION: Compared with [18 F]FDG, [18 F]FAP-2286 PET/CT demonstrates superior performance for detecting bone metastases and provides more accurate N and M staging. These findings suggest that [18 F]FAP-2286 PET/CT may serve as a valuable alternative for the comprehensive evaluation of lung cancer patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ma Y, Liu G, Du B, et al. Fibroblast activation Protein-Targeted PET/CT using [18 F]FAP-2286 for the evaluation of lung cancer: A comparative study with [18 F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2025. PMID: 40773018. doi:10.1007/s00259-025-07495-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。